Director H. Thomas Watkins to resign; executive compensation and equity grants for 2022

Vanda Pharmaceuticals Inc.

H. Thomas Watkins, director since 2006, will resign at 2022 Annual Meeting; board to shrink from 6 to 5.
CEO Mihael Polymeropoulos awarded 2021 bonus of $596,744; 2022 base salary $815,140 and target bonus 80%.
2022 option grants at $11.36/share: CEO receives 275,000 options and 115,000 RSUs.
CFO Kevin Moran 2021 bonus $175,473; 2022 base $426,120 and target 45%; option for 77,500 shares.
Aranthan Jones resigned as Chief Corporate Affairs Officer effective Oct 2021.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Aranthan "AJ" Jones II

Chief Corporate Affairs and Communications Officer

VNDA · Vanda Pharmaceuticals Inc.

Effective: 2021-10-26
Filed: March 1, 2022, 6:59 PM ET

Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.

Departed

H. Thomas Watkins

Class I director

VNDA · Vanda Pharmaceuticals Inc.

Filed: March 1, 2022, 6:59 PM ET

H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aranthan "AJ" Jones II resigned as Chief Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..

Action: resigned
Role: Chief Corporate Affairs and Communications Officer

Exact text from the filing

Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

H. Thomas Watkins resigned as Class I director at Vanda Pharmaceuticals Inc..

Action: resigned
Role: Class I director

Exact text from the filing

H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders

View on SEC.gov

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-061308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.